XTL Biopharmaceuticals
XTLB
3 hedge funds and large institutions have $699K invested in XTL Biopharmaceuticals in 2020 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
36% more capital invested
Capital invested by funds: $515K → $699K (+$184K)
0% more funds holding
Funds holding: 3 → 3 (0)
0% more ownership
Funds ownership: 0.02% → 0.02% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.46K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NC
1
Noked Capital
Tel Aviv,
Israel
| $316K | – | – | – |
|
|
NI
2
Noked Israel
Ramat Hasharon,
Israel
| $316K | – | – | – |
|
|
3
Morgan Stanley
New York
| $67K | +$2.46K | +475 | +5% |
|
XTLB Hedge Fund Activity: Q2 2020 in Review
3 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q2 2020, worth a combined $699K — up 36% from $515K a quarter earlier.
Fund positioning in XTLB was balanced in Q2 2020: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $2.46K.
- 3 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $699K of XTL Biopharmaceuticals stock for Q2 2020, up 36% quarter-over-quarter.
- 0 funds opened new XTL Biopharmaceuticals positions in Q2 2020 and 0 closed out.
- The largest XTL Biopharmaceuticals buyer in Q2 2020 was Morgan Stanley, an estimated $2.46K added.
Based on aggregated 13F filings for Q2 2020.